Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say

Apellis Pharmaceuticals, Inc. (APLS) reported $166.8 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.2$0.74 for the same period compares to -$0.54 a year ago. The reported revenue represents a surprise of -13.33$192.44 million. With the consensus EPS estimate being -$0.36, the EPS surprise was -105.56%. View all Key Company Metrics for Apellis Pharmaceuticals here>>> Shares of Apellis Pharmaceuticals have retur ...